The Microbicides Trial Network released promising results from its “MTN-007” Phase I safety and acceptability study, funded by the National Institutes of Health, looking at a new formulation of one percent tenofovir gel for rectal use Tuesday. The results were presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Earlier formulations […]
Investigators gave more details about the positive results of the Partners PrEP Study Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. The study of 4,700 HIV discordant couples (where one partner is HIV-infected and the other is not) looked at the potential of two different antiretrovirals for pre-exposure prophylaxis (PrEP) for […]
Another arm of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial has been discontinued, the National Institute of Allergy and Infectious Diseases at the National Institutes of Health announced Friday. The Data Safety Monitoring Board (DSMB) recommended the discontinuation of the daily one percent tenofovir vaginal gel arm of the study during […]
A scientific review board has closed down the oral tenofovir arm of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study looking at pre-exposure prophylaxis (PrEP) HIV prevention interventions among women in Africa. The Microbicides Trial Network, responsible for the study, made the announcement Wednesday. VOICE is the first study to compare the […]
The following is a guest blog post by Mitchell Warren, executive director of AVAC – Global Advocacy for HIV Prevention. Recent news about HIV/AIDS has focused on the good – promising trial results that prove the same antiretroviral (ARV) drugs used to treat HIV can also prevent HIV infections; and the bad – retreats in […]
MSNBC “Hardball” host Chris Matthews interviewed Director of the National Institute of Allergy and Infectious Disease at the National Institutes of Health Dr. Anthony Fauci at a Capitol Hill briefing Tuesday in commemoration of 30 years of the AIDS pandemic, hosted by the Foundation for AIDS Research (amfAR).
The interview covers topics from the latest scientific developments in combating the disease, challenges to maintaining federal funding, and an assessment of President Obama’s leadership in the fight against AIDS.
Dr. Anthony Fauci speaks out on treatment as prevention, pre-exposure prophylaxis and the way forward
More details were fleshed out on several compelling studies finding antiretroviral treatment is effective in preventing HIV infection – two pre-exposure prophylaxis studies as well as a large study (HPTN 052) looking at treatment of HIV infected persons in stable discordant partnerships that showed significant protection for the uninfected partner.
Science Speaks addressed these new studies and other topics Monday evening with Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, Dr. Anthony Fauci at the 2011 International AIDS Society meeting in Rome.
A pre-meeting session at the International AIDS Society conference in Rome was originally expected to feature the release of World Health Organization (WHO) guidance on HIV counseling and testing and access to antiretroviral therapy (ART) for “sero-discordant couples” – where one partner is HIV-infected and the other is not. Instead, the session highlighted a “work in progress” in the context of clinical trial results confirming the efficacy of HIV treatment and pre-exposure prophylaxis (PrEP) using antiretrovirals as HIV prevention…